Lilotomab
CAS No. 1453362-55-4
Lilotomab( —— )
Catalog No. M36808 CAS No. 1453362-55-4
Lilotomab (HH1), a murine anti-CD37 monoclonal antibody, demonstrates anti-tumor activity by reducing clonogenic survival .
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameLilotomab
-
NoteResearch use only, not for human use.
-
Brief DescriptionLilotomab (HH1), a murine anti-CD37 monoclonal antibody, demonstrates anti-tumor activity by reducing clonogenic survival .
-
DescriptionLilotomab (HH1) is a murine anti-CD37 monoclonal antibody. Lilotomab reduces clonogenic survival. Lilotomab shows anti-tumor activity.
-
In VitroApoptosis Analysis Cell Line:Ramos, DOHH2, Rec-1 cells Concentration:40?μg/mL Incubation Time:18 h Result:Induced apoptosis in DOHH2 cells.
-
In VivoAnimal Model:SCID mice (DOHH2 cell xenografts)Dosage:0.5?mg/kg Administration:I.v.; once Result:Inhibited tumor growth and increased mouse survival.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1453362-55-4
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Malenge MM, et al. 177Lu-Lilotomab Satetraxetan Has the Potential to Counteract Resistance to Rituximab in Non-Hodgkin Lymphoma. J Nucl Med. 2020 Oct;61(10):1468-1475.?
molnova catalog
related products
-
Hydroxyquinoline
8-Hydroxyquinoline is a monoprotic bidentate chelating agent, exhibits antiseptic, disinfectant, and pesticide properties.
-
pyridostigmine
Pyridostigmine?is an?acetylcholinesterase inhibitor?that can treat myasthenia gravis by increasing acetylcholine at the postsynaptic motor endplate.
-
3-Epiursolic acid
3-Epiursolic acid may have antiinflammatory activity, it shows inhibition on Cathepsins L (catL), the IC50 value of 6.5 μM, cathepsins L (catL) and B play an important role in tumor progression and have been considered promising therapeutic targets in the development of novel anticancer agents.
Cart
sales@molnova.com